within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX17_Evinacumab;

model Evinacumab
  extends Pharmacolibrary.Drugs.ATC.C.C10AX17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10AX17</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Evinacumab is a fully human monoclonal antibody that inhibits angiopoietin-like protein 3 (ANGPTL3). It is indicated for use as an adjunct to other lipid-lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH). The drug has received FDA approval for this condition.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on healthy subjects and patients with HoFH after intravenous administration of evinacumab. Typical population PK data.</p><h4>References</h4><ol><li><p>Harada-Shiba, M, et al., &amp; Catapano, AL (2020). A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. <i>Atherosclerosis</i> 314 33–40. DOI:<a href=&quot;https://doi.org/10.1016/j.atherosclerosis.2020.10.013&quot;>10.1016/j.atherosclerosis.2020.10.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33130482/&quot;>https://pubmed.ncbi.nlm.nih.gov/33130482</a></p></li><li><p>Bihorel, S, et al., &amp; Harnisch, L (2025). Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged &lt; 5 Years With Homozygous Familial Hypercholesterolemia. <i>CPT: pharmacometrics &amp; systems pharmacology</i> None –. DOI:<a href=&quot;https://doi.org/10.1002/psp4.70017&quot;>10.1002/psp4.70017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40095766/&quot;>https://pubmed.ncbi.nlm.nih.gov/40095766</a></p></li><li><p>Bihorel, S, et al., &amp; Harnisch, L (2025). Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia. <i>CPT: pharmacometrics &amp; systems pharmacology</i> None –. DOI:<a href=&quot;https://doi.org/10.1002/psp4.70016&quot;>10.1002/psp4.70016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40095399/&quot;>https://pubmed.ncbi.nlm.nih.gov/40095399</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Evinacumab;
